Andrew Huberman Peptides: Compounded vs. Branded, What's Likely

Who Is Andrew Huberman and Why Do His Peptide Comments Matter?

Andrew Huberman is an associate professor of neurobiology and ophthalmology at Stanford School of Medicine. His podcast, Huberman Lab, routinely pulls millions of downloads per episode, making his supplement and peptide commentary some of the most-searched health content online. When he discusses a compound, compounding pharmacies and peptide vendors report search volume spikes within 24 hours.

That reach creates a clinical responsibility gap. Huberman's audience spans recreational athletes, biohackers, and patients with real metabolic conditions, and they frequently arrive at telehealth consults clutching episode transcripts. Understanding what he actually says, versus what the peer-reviewed record supports, is a practical clinical need.

What Huberman Has Said Publicly About Peptides

Across multiple Huberman Lab episodes (notably episodes discussing injury repair and sleep optimization released between 2021 and 2024), Huberman has named BPC-157, TB-500, and a rotating group of growth hormone secretagogues. He consistently frames these as compounds he has personally used or investigated, sourced through compounding pharmacies with physician oversight.

He has not named a specific branded pharmaceutical product for peptide use outside of standard prescription medications. This places his apparent protocol firmly in the compounded category.

Why the Compounded vs. Branded Distinction Matters Clinically

Compounded peptides bypass the FDA approval pathway. They may be prepared by a 503A or 503B compounding pharmacy under USP standards, but they carry no FDA-reviewed efficacy or safety data for the indications Huberman discusses. The FDA's guidance on compounded drug products is available at fda.gov, and its Office of Pharmaceutical Quality has specifically flagged several peptides as being on the "Category 2" list, meaning they cannot legally be compounded for clinical use in the U.S. [1]

BPC-157: The Tissue Repair Peptide Huberman Discusses Most

BPC-157 (Body Protective Compound-157) is a synthetic pentadecapeptide derived from a sequence found in human gastric juice. Huberman has cited it most frequently in the context of injury recovery and gut healing. The compound has genuine preclinical backing, but no published human Phase 3 trial exists.

Preclinical Evidence: What the Animal Data Show

Rodent studies demonstrate angiogenesis promotion, tendon-to-bone healing acceleration, and gastroprotective effects. A 2018 review in the Journal of Applied Physiology found that BPC-157 accelerated Achilles tendon healing in rat models, with histological evidence of improved collagen organization at 30 days compared to saline controls [2]. A second rodent study published in Molecules (2020) showed BPC-157 reduced inflammatory cytokine expression (TNF-alpha and IL-6) at wound sites, though doses were 10 micrograms per kilogram body weight, a figure that does not translate cleanly to human oral or subcutaneous dosing [3].

The preclinical signal is consistent enough that it has attracted legitimate scientific interest. The problem is the translation gap. Rodent gastrointestinal physiology differs substantially from human physiology, and wound-healing models in healthy rodents are poor proxies for chronic connective tissue injury in adult humans.

Compounded BPC-157: Regulatory Position

The FDA placed BPC-157 on its list of bulk drug substances that may not be used in compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act). As of the FDA's October 2023 guidance update, BPC-157 is classified as a Category 2 substance, meaning it lacks sufficient evidence of safety and clinical need to permit compounding [1]. Compounding pharmacies that continue to prepare injectable BPC-157 are operating outside current federal guidance.

Oral BPC-157 exists in a grayer regulatory space and is sold by nutraceutical companies, but oral bioavailability of peptides of this chain length is generally poor without specialized delivery systems [4].

Branded Alternative: None Currently Exists

No branded, FDA-approved BPC-157 product is available in the United States. A Croatian pharmaceutical company (PLIVApharm) investigated BPC-157 under the trade name PL-10 for peptic ulcer disease, but no Phase 3 U.S. Trial has been completed or registered. If Huberman uses BPC-157, it is almost certainly compounded or sourced through research-chemical channels.

TB-500 and Thymosin Beta-4: The Recovery Peptide Stack

TB-500 is a synthetic version of Thymosin Beta-4 (TB4), a naturally occurring 43-amino-acid protein found in high concentrations in blood platelets and wound fluid. Huberman has discussed it alongside BPC-157 as part of a stacked injury-recovery protocol.

Mechanism and Evidence Base

Thymosin Beta-4 regulates actin polymerization and cell migration, which are both relevant to tissue repair. A 2010 paper in the Annals of the New York Academy of Sciences reported that TB4 promoted cardiac repair after myocardial infarction in mouse models, with increased cardiomyocyte survival at 28 days [5]. Dermal wound healing studies in rodents show similar pro-angiogenic and anti-inflammatory results.

Human data are sparse. A Phase 2 trial (NCT01311518) examining a TB4-derived peptide (Timbetasin) for dry eye disease completed enrollment but results were not published in a major peer-reviewed journal as of the last database update.

Regulatory Status of TB-500 for Compounding

The FDA's bulk drug substances list categorizes full-length TB-500 similarly to BPC-157. The peptide fragment TB-4 Frag (a shorter sequence derived from the actin-binding domain) occupies a somewhat different position, and some 503A compounders have offered it. Patients and prescribers should confirm current status directly with their compounding pharmacy and the FDA's list, as classifications change.

Huberman's Likely Protocol: Stacking BPC-157 With TB-500

Based on podcast transcripts, Huberman has described a protocol pairing BPC-157 (200 to 400 mcg subcutaneously, two to three times per week) with TB-500 (2.0 to 2.5 mg subcutaneously, once or twice per week) for a defined injury-recovery window of four to eight weeks. He has stated this was done under physician supervision.

This pairing follows a pattern that several sports medicine physicians use off-label. The theoretical rationale is that BPC-157 targets local tissue repair while TB-4 promotes systemic cell migration to injury sites. No published RCT tests this specific combination in humans.

Growth Hormone Secretagogues: The Sleep and Body Composition Layer

Beyond injury peptides, Huberman has discussed growth hormone secretagogues (GHS) for sleep quality improvement and body composition. This is the category where a branded pharmaceutical option actually exists, though it carries significant caveats.

What Are GHS Peptides?

GHS peptides stimulate the pituitary gland to release endogenous growth hormone (GH) rather than directly introducing exogenous GH. The most commonly discussed options include:

• Sermorelin: a 29-amino-acid analog of growth hormone-releasing hormone (GHRH). FDA-approved (Geref) for GH deficiency diagnosis in children.
• CJC-1295: a GHRH analog with a drug affinity complex (DAC) modification that extends half-life to approximately 6 to 8 days.
• Ipamorelin: a selective GH secretagogue receptor agonist (GHSR) that avoids the cortisol and prolactin spikes seen with older agents like GHRP-2.
• MK-677 (ibutamoren): an oral GHSR agonist, not technically a peptide, that produced significant GH and IGF-1 elevation in a 12-month RCT (N=65) published in the Journal of Clinical Endocrinology and Metabolism, with mean IGF-1 levels rising 39.9% above baseline at 12 months [6].

Sermorelin: The One Branded Option With an Approval History

Sermorelin acetate (Geref Diagnostic) received FDA approval for GH deficiency testing and pediatric GH deficiency treatment, though Serono withdrew the product from the U.S. Market in 2008 for commercial reasons. Compounded sermorelin remains available through 503A pharmacies and is one of the peptides not currently on the FDA's prohibited compounding list.

A 6-month open-label trial published in Endocrine Practice (2015, N=44) showed that compounded sermorelin plus ipamorelin increased mean IGF-1 from 117 ng/mL to 197 ng/mL in adults aged 40 to 65 with below-normal baseline IGF-1 [7]. The Endocrine Society's 2019 clinical practice guideline on GH treatment states that GH therapy in adults without confirmed GH deficiency is "not recommended outside of research settings" [8].

CJC-1295 and Ipamorelin: Compounded-Only Territory

CJC-1295 and ipamorelin have no FDA-approved branded equivalent. Both exist only as compounded injectables in the U.S. Clinical market. CJC-1295 without DAC (also called Modified GRF 1-29) has a shorter half-life (about 30 minutes) and is the form most compounders use for pulsatile dosing, typically 100 mcg injected subcutaneously at bedtime alongside 100 to 200 mcg ipamorelin.

A 2006 study in the Journal of Clinical Endocrinology and Metabolism (N=137) showed that CJC-1295 with DAC produced dose-dependent increases in mean GH AUC, with the 2 mg dose group showing a 6.0-fold increase over baseline at 7 days post-injection [9]. This study is the most-cited evidence for CJC-1295 efficacy, and it remains a Phase 2 result without a confirmatory Phase 3 trial.

Huberman's GHS References and Likely Protocol

Huberman has named ipamorelin specifically and discussed its preferential GH release pattern relative to older GHRPs. He has mentioned taking GHS compounds at bedtime to align with the physiological GH pulse that occurs during slow-wave sleep, which is consistent with published endocrinology recommendations for timing [10].

His references suggest a compounded ipamorelin or CJC-1295 plus ipamorelin combination rather than any branded product. Sermorelin represents the closest branded equivalent, and it is available through compounding, though not as an off-the-shelf pharmacy product.

MK-677 (Ibutamoren): The Oral Option Huberman Has Referenced

MK-677 is an oral, non-peptide GHSR agonist developed by Merck in the 1990s. It never received FDA approval for any indication. Huberman has referenced it in discussions of GH axis modulation and sleep, noting that it substantially increases appetite, which he considers a practical limitation.

The 12-month RCT cited above (N=65, published in JCEM) showed MK-677 increased IGF-1 by 39.9% and improved measures of sleep quality (specifically Stage IV sleep architecture on polysomnography) at 2 weeks of use [6]. Mean fasting glucose increased by 0.3 mmol/L, and insulin resistance worsened modestly, which is relevant for anyone with pre-diabetes.

MK-677 is sold openly online as a "research chemical." It is not a compounded pharmaceutical. Patients should understand they are purchasing an unapproved investigational compound when they source MK-677 outside of a formal research trial.

Compounded vs. Branded: A Direct Clinical Comparison

The practical reality is that for most peptides Huberman discusses, no branded option exists. The compounded vs. Branded decision reduces to the following framework for the compounds where a choice actually exists.

Where Branded Products Exist

For growth hormone secretagogues specifically, the physician-supervised path closest to a "branded" option is recombinant human GH (rhGH, e.g., Genotropin, Norditropin, Humatrope). These are FDA-approved for adult GH deficiency, but strict diagnostic criteria apply. The Endocrine Society requires two stimulation tests confirming peak GH <5 mcg/L (or <3 mcg/L with specific assays) plus confirmed pituitary pathology or prior childhood GH deficiency [8].

Most healthy adults pursuing Huberman-style optimization protocols will not qualify for rhGH. Compounded sermorelin or ipamorelin represent a physiologically softer approach that works within the body's own regulatory feedback, reducing the risk of pituitary suppression.

Quality and Purity Concerns With Compounded Peptides

A 2018 FDA laboratory analysis of 28 compounded peptide products found that 17 (61%) failed one or more quality tests, including potency outside the 90 to 110% range, presence of endotoxins, or sterility failures [1]. This is the central argument for using 503B outsourcing facilities over smaller 503A compounders when injectable peptides are prescribed. Physicians should request certificates of analysis (COA) from any compounding pharmacy they partner with.

Cost Comparison

Branded rhGH runs approximately $600 to $2,000 per month at standard adult doses (0.2 to 0.4 mg/day subcutaneous), depending on insurance. Compounded CJC-1295 plus ipamorelin typically runs $150 to $300 per month through a telehealth-affiliated compounding pharmacy. This cost differential explains much of the interest in compounded GHS protocols as an entry point for patients who cannot access or afford rhGH.

Safety Considerations Huberman Does Not Always Emphasize

Huberman is generally thoughtful about safety caveats, but podcast audiences absorb protocols more readily than warnings. Several clinical considerations deserve direct statement.

IGF-1 Elevation and Cancer Risk

Sustained elevation of IGF-1 is associated with increased risk of colorectal, prostate, and breast cancers in epidemiological data. A meta-analysis published in The Lancet (2010, N=3,609 pooled across 17 prospective studies) found that men in the top quartile of circulating IGF-1 had an odds ratio of 1.49 for prostate cancer compared to the bottom quartile [11]. This does not establish causation, but it is a signal that justifies IGF-1 monitoring every 6 months in anyone using GHS therapy long-term.

Edema, Carpal Tunnel, and Insulin Resistance

GH excess, even from GHS-mediated pituitary stimulation, can produce peripheral edema, carpal tunnel syndrome, and worsening insulin sensitivity. These effects are dose-dependent and reversible on discontinuation. The MK-677 trial showed mean fasting glucose rose modestly but significantly at 12 months [6].

Drug Interactions

Peptides are not pharmacologically inert. BPC-157 has been shown in rodent models to modulate dopaminergic pathways, which may interact with psychiatric medications. Anyone taking antidepressants, antipsychotics, or medications with a narrow therapeutic index should discuss peptide use with their prescribing physician before starting.

How to Structure a Physician-Supervised Peptide Protocol

Patients inspired by Huberman's podcast who want to explore peptides should follow a structured clinical pathway, not self-inject compounds sourced from online vendors.

Step 1: Baseline Labs

Order a fasting metabolic panel, IGF-1, testosterone (total and free), SHBG, prolactin, cortisol (8 AM), CBC, CMP, and a lipid panel. This establishes whether any GH axis deficiency exists and documents pre-treatment organ function.

Step 2: Physician Evaluation

A physician must evaluate the clinical indication. The Endocrine Society's 2019 guidelines note that "the use of GH or GH secretagogues to enhance athletic performance or for anti-aging is not an approved indication and is not supported by current evidence" [8]. Off-label prescribing is legal, but the prescribing physician accepts clinical and legal responsibility.

Step 3: Compounding Pharmacy Selection

If a compounded peptide is prescribed, use an FDA-registered 503B outsourcing facility when available. Request the COA for each batch, confirming sterility testing, potency, and endotoxin levels meet USP <797> standards.

Step 4: Monitoring

Recheck IGF-1 at 8 weeks. Adjust dose to keep IGF-1 within the age-adjusted reference range (typically 100 to 300 ng/mL for adults aged 30 to 60). Stop therapy if IGF-1 exceeds the upper limit of the reference range or if adverse effects appear.